Evidence map›Paper›PMID 38911997›Full record

ReviewPsoriasis (Auckland, N.Z.)2024

The Perspective of Cannabidiol in Psoriasis Therapy.

Ana Maria Alexandra Stanescu, Gabriel Cristian Bejan, Mihaela Daniela Balta, Octavian Andronic, Cristian Toma, Stefan Busnatu

Abstract readReview
In one paragraph

Review in Psoriasis (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Beyond Cannabidiol: The Contribution ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  4. Effects of a Cannabinoid-Based Phytocomplex (Pain ReliefAnimals : an open access journal from MDPI · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana Maria Alexandra StanescuDepartment 5, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Gabriel Cristian BejanDepartment 5, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Mihaela Daniela BaltaDepartment 5, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Octavian AndronicDepartment 10, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.ORCID 0000-0002-9053-0018
Cristian TomaDepartment 3, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Stefan BusnatuDepartment 4, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a chronic skin condition that can significantly impact the quality of life of those affected. As an autoimmune disease, it can lead to itchy, painful, and scaly patches on the skin. Although various treatments, including topical creams, phototherapy, and systemic medications, are currently available, they may not always offer effective relief and can have side effects. Researchers have thus been exploring the potential benefits of non-psychoactive compounds such as CBD, found in Cannabis sativa plants, for treating psoriasis. CBD treatment may reduce inflammation, oxidative stress, itching, abnormal proliferation of keratinocytes, and may increase hydration. This review aims to provide an overview of the existing literature on the potential uses of CBD for psoriasis treatment.

Indexed as

cannabidiolnon-psychoactive compoundspsoriasistreatment

Identifiers

PMID38911997
PMCPMC11193997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.